Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.02.07
- Author:
Wensheng ZHOU
1
;
Wei ZHANG
2
;
Baohui HAN
2
Author Information
1. Shanghai Jiao Tong University School of Medicine, Shanghai, 200240, China.
2. Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai, 200030, China.
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor;
Exon 20;
Insertion mutation;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2020;23(2):118-126
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer has the highest morbidity and mortality among malignant tumors worldwidely. Targeted therapy related to non-small cell lung cancer (NSCLC) is the research hotspot in recent year. The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has brought a huge change in the treatment of patients with EGFR mutation. The patients with EGFR exon20 insertion are specific cohort in NSCLC. Reviewing the clinical researches to EGFR exon20 insertion mutation positive NSCLC, as well as summarizing character, testing methods and treatment, will provide a help for clinical application, bringing more benefits for patients at the same time.
